Alpine Immune Sciences Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alpine Immune Sciences Inc.
BioMarin teams with Skyline on gene therapies for cardiovascular disease. Myrtelle discloses licensing of gene therapy for Canavan disease from Pfizer earlier in 2021.
The merger closed in May, so the second quarter earnings report will be the first presentation of the combined company’s performance and outlook.
The JAK1 inhibitor showed skin clearance and itch reduction in first of three Phase III trials. Analysts say blockbuster atopic dermatitis indication is possible if data hold up in ongoing studies.
Deal Snapshot: Set to begin a Phase II study that Alpine will complete, ALPN-101 is a dual inhibitor of CD28 and ICOS that may offer a new treatment option in SLE.
- Large Molecule
- Other Names / Subsidiaries
- N30 Pharmaceuticals, Inc.
- Nivalis Therapeutics, Inc.